Mentor to roll out PerImmune physician-office bladder cancer test kit this fall, CEO says.
This article was originally published in The Gray Sheet
MENTOR TO BEGIN MARKETING PERIMMUNE PHYSICIAN OFFICE BLADDER CANCER TEST THIS FALL under a marketing agreement announced June 16 by Mentor Chairman and CEO Christopher Conway at a Piper Jaffray investment conference in Minneapolis. The pact provides Mentor with exclusive worldwide distribution rights to Rockville, Maryland-based PerImmune's urine-based immunoassay, which is intended for use in conjunction with cystoscopy to aid in the management of bladder cancer patients.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.